Consequences of disclosing clinical trial results: Evidence from the food and drug administration amendments act
We examine how the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007, which requires additional disclosures regarding clinical trial results, impacts information asymmetry between the disclosing pharmaceutical firm and capital market participants, the general public, academics, and pr...
Saved in:
Main Authors: | BORVEAU, Thomas, CAPKUN, Vedran, WANG, Yin |
---|---|
Format: | text |
Language: | English |
Published: |
Institutional Knowledge at Singapore Management University
2020
|
Subjects: | |
Online Access: | https://ink.library.smu.edu.sg/soa_research/1838 https://ink.library.smu.edu.sg/context/soa_research/article/2865/viewcontent/SSRN_id3533305.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Singapore Management University |
Language: | English |
Similar Items
-
Do firms respond to peer disclosures? Evidence from disclosures of clinical trial results
by: CAPKUN, Vedran, et al.
Published: (2023) -
Do firms respond to peer disclosures? Evidence from clinical trial disclosures
by: CAPKUN, Vedran, et al.
Published: (2021) -
Disclosure regulation: Past, present, and future
by: KOTHARI, S.P., et al.
Published: (2022) -
Disclosure and closeness: Effect of disclosing certain kinds of information about other individuals
by: Go, Jasper Alvin A., et al.
Published: (2009) -
The efficacy and safety of eperisone in patients with cervical spondylosis: Results of a randomized, double-blind, placebo-controlled trial
by: Bose, K.
Published: (2013)